Blue Team Survival Guide (Revised 2/27/2012, JL Goralski MD and JE Pittman MD)
|
|
- Kathleen Greene
- 5 years ago
- Views:
Transcription
1 Blue Team Survival Guide (Revised 2/27/2012, JL Goralski MD and JE Pittman MD) Rounds: - Meet either at desk at 5 Children s (weekdays at 8:30AM) or in 5 Children s Conference Room in CICC (weekends at 8AM) - It is usually a pretty large team Attending, fellow, pulmonary home IV nurse (Benjamin Butler), ward team coordinator (Meredith George), dietician (Kelly Baumgartner/Kimberly Stephenson), pharmacist, respiratory therapist (Kelli Johnson), resident, intern and medical students - Useful to know/ present recent PFT s, best in past year, recent sputum culture results. PFT s presented in the following order: forced vital capacity (FVC), forced expiratory flow in one second (FEV1), forced expiratory flow 25:75 (FEF 25:75), all given in percent predicted. When the attending asks for the best in the last year, they are usually referring to the best FEV1. - In your presentation and the daily progress note, comment on the respiratory complaints that brought them into the hospital. i.e., cough continues to improve and is less productive, wheezing is less pronounced, etc. Always make sure to mention how much oxygen the child is requiring. - When you go in the room as a team, the Blue Team intern should lead the discussion with the family/child. This will help establish you as an integral team member in the parents eyes. Admissions: - Look at recent clinic notes- these are usually very detailed, accurate, and useful. - Three different admission order sets in CPOE for Ped Cystic Fibrosis PUL and Meds, Patient care, and Labs - If the child is being admitted following a bronchoscopy, we very often see fever in the first hours post-operatively. These fevers do not require a typical sepsis workup. Note also that if the child has had bronchoalveolar lavage (BAL) the CXR will often look like pneumonia in the segment that was lavaged. CXR cannot distinguish between BAL fluid and pneumonia. Usually a CXR is not even ordered postbronch, unless it is needed to confirm PICC placement. Inpatient CF admissions: All need nutrition consult, physical therapy consult, and respiratory therapy consult. Usually obtain sputum cultures on admission if not recently obtained in clinic. Labs that are done on an annual basis include sputum for AFB, liver function testing, PT/INR, Vitamin A, D, and E levels, and IgE. If these have not been done in the last year, order them with the admission labs except for vitamin levels, which are often drawn at the end of admit (levels are often low with acute illness). Annual screening also includes a CXR, audiology evaluation if he/she has been on aminoglycosides, and an oral glucose tolerance test (age >10). Do not order these upon admission, but feel free to bring it up on rounds that the patient is not up to date. Meds usually updated in WebCis; this list reflects what the patient should be taking but it may not be what they are actually using. When in doubt, point out the discrepancy to the attending/fellow. Choosing antibiotics for CF: When choosing an antibiotic regimen for the patient, the pulmonary team generally looks at cultures over the past year and tries to cover all the known bacteria. Older kids usually respond well to regimens that have been used in the past, so check the old discharge summaries. Patients may respond to regimens to which they appear resistant by sensitivities. Pseudomonas and Burkholderia are always double-covered (not with 2 agents of the same class (e.g. ceftazidime and zosyn both B-lactam drugs), but occasionally regimens are designed that include drugs that have been shown to have in vitro resistance. You should try to
2 come up with a regimen on your own that you think would be adequate coverage, but always run the antibiotics by the fellow before ordering them. Dosing of antibiotics is often different in CF patients (different metabolism/clearance, need to get penetration into mucus) check guide below and speak with pharmacy. Labs are done routinely to screen for toxicity. In general, once on a stable dose of an aminoglycoside, check BUN/Cr twice weekly, trough levels weekly. Depending on the drug, weekly CBC and LFT s may also be necessary. Discharges - It is crucial to keep the brief discharge summary up to date. The home IV coordinators fax this to the home care companies as the preliminary orders for medications, often 2-3 days before the patient is discharged. If you change a dose on a medication that the child will be going home with, update it in the brief discharge summary so the pharmacy can mix the correct dose. - If the patient has been admitted for a CF exacerbation, use the following term as your discharge diagnosis CF bronchopneumonia caused by (pseudomonas, ORSA, etc.) This is the way it needs to be documented for billing purposes. - If at all possible, make sure follow up in pulmonary clinic for CF patients is scheduled prior to discharge - Follow-up visit should typically include PFTs, which are scheduled separately (speak to schedulers or Meredith PFT clinic code is 662). Pulmonary Function Tests (PFT s) or spirometry: - FVC / FEV1 / FEF 25%:75% are reported in both absolute liters and percent predicted for that age/ sex/ race - PFT s results will be in patient s paper chart as well in Pulmonary Results in WebCis (though these usually take 1-2 days to show up); the inpatient fellow is often paged with the results as well - PFT s usually obtained either upon admission or at most recent clinic visit - PFT s usually obtained weekly in CF patients to assess response to therapy - No PFT s in someone who has a pneumothorax! Miscellaneous meds: (more information below) - Pancreatic enzymes (Creon, Pancreaze, Zenpep, Ultrase) - weight based maximums and dosed in lipase units/kg per meal and per day. Maximum is typically 10-15,000 lipase units/kg/day. For example, Creon 12 means that there are 12,000 lipase units in each capsule of Creon. - Phytonadione (vit K) - 5 mg PO at least twice weekly while on antibiotic therapy since antibiotics also wipe out the good gut flora that converts Vit K; dosed daily if PT/INR already elevated on admission. - CF specific vitamins include SourceCF, ADEK, Vitamax, among others. These have the supplemental fat soluble vitamins that CF children have difficulty absorbing from their diet. - Pulmozyme (dornase alfa) inhaled once or twice daily to liquefy sputum to make it easier to cough out - Hypertonic saline (HS) - concentrations of 3%, 5.45%, or 7%. HS helps hydrate secretions and reduces exacerbation frequency. It is usually inhaled 2-4x daily. - inhaled antibiotics you may encounter include TOBI (inhaled tobramycin), Cayston (inhaled aztreonam), and colistin. All these treat pseudomonas; there is currently no inhaled therapy for staph. Be aware that when you say TOBI, that means the drug is being inhaled. Tobra indicates IV tobramycin very different in their toxicities! - In general, CF patients take their inhaled medications in the following order: albuterol, HS, airway clearance maneuver (VEST, flutter, acapella, CPT), pulmozyme, then inhaled antibiotics or inhaled corticosteroids. - NO IBUPROFEN for children receiving renal-toxic drugs. Give Tylenol instead for pain or fever.
3 Fat Soluble Vitamin Levels: A,D,E,K - CF patients have difficulty absorbing fat soluble vitamins, so they need to take extra CF-specific vitamins. Vitamin levels are screened for at least yearly and take about a week to come back. - INR obtained on admission (best surrogate for measuring functional deficiency of Vitamin K) if INR is elevated, Vit K may need to be dosed daily. IgE Levels: - Levels usually obtained on admission to screen for Allergic Bronchopulmonary Aspergillosis (ABPA), but takes several days to weeks to come back - > 500 is abnormal in CF (>1000 in asthma) but the trend is more important than any single value, so check back to their last value - If very high may treat with steroids/ antifungals for ABPA Chest Physiotherapy (Chest PT) - Usually done 4x per day while hospitalized +/- albuterol pre-treatment - Order Respiratory therapy consult - Can be manual or device driven (VEST, acapella, flutter, Metaneb, Duet) - needs to be coordinated with inhaled drugs to be most effective Central lines: - If a patient has a Port or gets a new PICC line, need to put order in CPOE to use it - Search CVAD, choose CVAD with Flushes (Pt GT 5kg) - Choose the appropriate line and complete the rest of the screens Asthma - Any child admitted to the PICU for asthma gets a pulmonary consult; most are transferred to Blue team before discharge if there is room - A new asthma order set and protocol is available. This will standardize care for asthma across services and locations (ED, PICU, Floor). This order set is not applicable for children under the age of 2, children admitted with viral bronchiolitis or croup, or those with a medical history of CF/chronic lung disease/ cardiac disease/ or airway anomalies (see attached protocol). - In transfer note, document history of asthma, current home asthma medications, previous hospitalizations or history of intubation, allergic/infectious triggers, PICU interventions (continuous albuterol therapy, IV SoluMedrol, IV magnesium, terbutaline drip and/or heliox). - Review and revise orders in CPOE, dump all the PICU-specific stuff (turn q2 hours, rhythm strip printouts q12, etc.) - Start on home controller medicines if not already started (Qvar, Flovent, etc.). Some kids are not on a controller medicine at home...they will be when they are discharged. Order oral prednisone if not on already. 1-2mg/kg, 60mg/day max. Usually 5 days total steroid therapy but guidelines are for 3-14 days of oral steroid therapy, so you can adjust depending on how the kid looks. - New asthma order set includes: Ability to do q2 albuterol on the floor x 3 then q3h x 4 Standard is high-dose MDI albuterol (4-8 puffs) instead of nebulized medication Pediatric Asthma Score Assessment (to follow treatment response, determine when to wean) Protocol-driven weaning of meds -Can go home when stable on home treatment and after asthma education completed. Prior to discharge, all patients must have an asthma action plan in place. Administer flu shots for those hospitalized during flu
4 season. Should have follow up appointment with pulmonary scheduled before discharge (typically in 1-2 months) - Asthma education on the Blue Team is provided by Kelli Johnson, RT or Lisa Alarcon, RN. For weekend discharges, RT s may help with asthma education. TRACHEOSTOMY -After a new trach is placed, the child remains in the PICU for 7 days post-op, until the first trach change (must be done by ENT to avoid creating a fistulous tract). - When you accept a tracheostomy patient, ensure the following is by bedside at all times. If anything is missing, inform the nurse. - Sign indicating size/type of tracheostomy tube, suction depth, and the day of the week for the scheduled trach change - A spare trach in the size that the child needs - A spare trach one size smaller. This is for emergency situations where you cannot get the trach back in. - Suctioning should only be done to the depth of the end of the trach tube. Any further and you are likely to cause granulation tissue and bleeding. During your time on Blue Team, you should develop proficiency in suctioning and changing trachs. - If a rapid response is called on a child with a trach due to respiratory distress or desaturations, try suctioning first. If no response, change the trach it may be plugged even if you don t get any secretions back. If you can t get the same size trach back in, use the smaller one and notify ENT. If all else fails, the tracheotomy site can be occluded with a finger or gauze/tape and the child bagged from above. - Trachs are often colonized with bacteria, so in general, don t send a trach aspirate unless there is clinical concern for infection (fever, increased WBC, change in trach secretions, etc.). - Don t be afraid of trachs! They are the most stable airways on the floor! Peds PFT Orders Charge Code Test Name CPT Code Arterial Blood Gas Draw Airway Resistance PD Carbon Mon Diffus Capacity PD Flow Vol Loop Pre/Post PD Lung Vol Body Box PD Lung Vol N2 Washout PD Max Insp/Exp Musc Press PD Maximum Voluntary Ventilation Respiratory Flow Vol Loop PD 94375
5 Spirometry Pediatric Reading List: Link to Website with miscellaneous readings on Pediatric Pulmonology: fibrosis
6 Medication Guidelines for Pediatric Cystic Fibrosis Patients Megan Young, Pharm.D. Pediatric Pharmacy Satellite Hours: Pediatric Pharmacy #: Blue Team Pharmacist Pager #: After 2330, call Central Pharmacy for questions: Oral Antibiotics Amoxicillin/Clavulanic Acid: 40 mg/kg/dose BID (max single dose = 2000 mg) 500 and 875 mg tablets; 200 and 400 mg chewables; XR tablets 1000 mg ES suspension 600 mg/5ml (less clavulanic acid). Cefpodoxime: 5 mg/kg/dose BID (max single dose = 400 mg) Cefuroxime Axetil: 20 mg/kg/dose BID (max single dose = 1 gram) If using suspension: 30 mg/kg/dose BID 250, and 500 mg tabs; (suspension 125 and 250 mg/5ml nonformulary, tastes terrible) Cephalexin: 25 mg/kg/dose QID (max single dose = 1 gram) 250 and 500 mg capsules; 125 and 250 mg/5ml suspension Ciprofloxacin: 20 mg/kg/dose BID (max single dose = 1 gram) 250, 500, and 750 mg tabs; XR tablets 500 and 1000 mg; 250 and 500 mg/5ml suspension ** Do not give oral suspension via a G-Tube or NG tube Clarithromycin: 15 mg/kg/dose BID (max single dose = 500 mg) 250 and 500 mg tablets; XL tablets 500 mg; 125 and 250 mg/5ml suspension Clindamycin: 10 mg/kg/dose TID (max single dose = 600 mg) 150, and 300 mg capsules; 75 mg/5ml suspension Dicloxacillin: 25 mg/kg/dose QID (max single dose = 500 mg) 250, and 500 mg capsules Doxycycline: 5 mg/kg initial dose, followed by 2.5 mg/kg/dose BID (max single dose = 100 mg) 50 and 100 mg capsules, capsules may be opened Levofloxacin: < 5 yr: 10 mg/kg/dose q 12 hours (max single dose = 750 mg) > 5 yr: 10 mg/kg/dose q 24 hours (max single dose = 750 mg) > 50 kg 750 mg q 24 hours
7 * Consider continuing q 12 hour dosing even if > 5 yr 250, 500, and 750 mg tablets; 25mg/mL liquid Linezolid: < 12 yr: 10 mg/kg/dose q 8 hours (max single dose = 600 mg) 12 yr: 10 mg/kg/dose q 12 hours (max single dose = 600 mg) * Consider continuing q 8 hour dosing if > 12 yr but less than 45 kg 600 mg tablets (may cut tablets in-half for 300mg doses); 20 mg/ml suspension Minocycline: 4 mg/kg initial dose, followed by 2 mg/kg/dose BID (max single dose = 100 mg) 50 and 100 mg capsules, capsules may be opened TMP/SMX (trimethoprim/sulfamethoxazole): mg/kg/dose of TMP component BID 80 mg TMP/400 mg SMX tab; 160 mg/800 mg SMX DS tab; 40 mg TMP/200 mg SMX/5mL suspension **May divide TID/QID for nausea with BID dosing** Intravenous Antibiotics Double-cover Pseudomonas, do not combine anti-pseudomonal beta lactams, as they can be antagonistic Initial doses for Tobramycin and Amikacin should be based on patients previous doses; see pharmacist or WebCis consult note for past dosing information Amikacin doses can be calculated from old gentamicin and tobramycin pharmacokinetics If patient has not received aminoglycosides in the past, use the following guide for dosing Amikacin: 20 mg/kg/dose q 12 hours Aztreonam: 50 mg/kg/dose q 6 hours (max single dose = 2 grams) Cefepime: 50 mg/kg/dose q 8 hours (max single dose = 2 grams) Ceftaroline: 600 mg IV q12 hours (minimum weight = 30 kg no pediatric dosing) Ceftazidime: 75 mg/kg/dose q 8 hours (max single dose = 2 grams) Ceftriaxone: 50 mg/kg/dose q 12 hours (max single dose = 2 grams) Cefuroxime: 75 mg/kg/dose q 8 hours (max single dose = 1.5 grams) Ciprofloxacin: 10 mg/kg/dose q 8 hours (max single dose = 400 mg) Clindamycin: 13.3 mg/kg/dose q 8 hours (max dose/day = 4.8 grams) Colistin: mg/kg/dose q 8 hours (max single dose = 100 mg) **Monitor renal function closely** Imipenem: 20 mg/kg/dose q 6 hours (max single dose = 1 gram) **May need to decrease dose to mg/kg/dose q6 hours due to nausea and vomiting** Levofloxacin: < 5 yr: 10 mg/kg/dose q 12 hours (max single dose = 750 mg) > 5 yr: 10 mg/kg/dose q 24 hours (max single dose = 750 mg) > 50 kg 750 mg q 24 hours
8 Linezolid: < 12 yo: 10 mg/kg/dose q 8 hours (max single dose = 600 mg) 12 yo: 10 mg/kg/dose q 12 hours (max single dose = 600 mg) * Consider continuing q 8 hour dosing if > 12 yr but less than 45 kg **Bacteriostatic** Meropenem: 40 mg/kg/dose q 8 hours (max single dose = 2 grams) **Reserve use for resistance to other antibiotics** **May need to decrease dose to mg/kg/dose q 6 hours due to nausea and vomiting** Oxacillin: 50 mg/kg/dose q 6 hours (max single dose = 2 grams) Piperacillin/Tazobactam: 100 mg/kg/dose q 6 hours (max single dose = 4 grams of piperacillin) Telavancin: 10 mg/kg q24 hours (minimum weight = 40 kg no pediatric dosing) Ticarcillin/Clavulanate: 100 mg/kg/dose q 6 hours (max single dose = 6 grams of ticarcillin) **Infuse doses > 3 g over 1 hour** Tobramycin/Gentamicin: 6 mg/kg/dose q 12 hours ** If aminoglycoside naïve and > 16 yr, start 5 mg/kg/dose q 12 hours Vancomycin: 25 mg/kg/dose q 8 hours Nontuberculous Mycobacterium Antibiotics Please start only ONE drug per day to assess for Nausea / Vomiting from each drug Recommended Regimens (vary by physician preference) Cefoxitin: 50 mg/kg/dose IV q 6 hours (max single dose 2 grams) For convenience at home may receive 3 g IV q8h Amikacin: 15 mg/kg/dose IV q 12 hours (if on > 2 drugs) **** Want measured peaks of **** Tigecycline: > 8 years: Day 1: 2 mg/kg/dose IV OTO (max single dose 100 mg) Day 2: 1 mg/kg/dose IV q 12 hours (max single dose 50 mg) **Data currently supports q 12 hour dosing research is being done on q 24 hour dosing. If using for indication other than NTM dosing interval is always q 12 hours Clarithromycin or Azithromycin*: * May substitute linezolid, fluoroquinolones, or imipenem Clarithromycin: 30 mg/kg/dose PO QHS (max single dose 1 gram) May divide as 15 mg/kg/dose PO q 12 hours for N/V
9 Azithromycin: 500 mg PO q 24 hours (> 40 kg) 250 mg PO q 24 hours (if < 40 kg) Antifungals (lots of drug interactions) Fluconazole: 12 mg/kg IV/PO q 24 hours (max single dose = 800 mg) 50, 100, 150, 200 mg tablets; 50 and 200mg/5mL suspension Itraconazole: 5 mg/kg PO q 12 hours (max single starting dose = 200 mg) 100 mg capsules, 50mg/5mL solution ** Give with food, acidic juice, or cola Give capsules with food, give suspension on an empty stomach (suspension has better absorption than capsules) Posaconazole: 10 mg/kg PO q12 hours (max single dose = 400 mg) 40mg/mL suspension Voriconazole: IV Loading Dose < 12 yr: 8 mg/kg q 12 hours x 2 doses IV Maintenance Dose < 12 yr: 7 mg/kg q 12 hours IV Loading Dose > 12 yr: 6 mg/kg q 12 hours x 2 doses on day 1 IV Maintenance Dose > 12 yr: 4 mg/kg q12 hours PO Loading Dose: 8 mg/kg/dose q 12 hours x 2 doses on day 1 (Max single dose = 400 mg) PO Maintenance Dose: 7 mg/kg/dose q 12 hours (Max single dose = 200 mg) PO available as 50 and 200 mg tablets; 40mg/mL suspension
10 Fluconazole Itraconazole Posaconazole Voriconazole Renally Dose Adjust Yes No No No, but do not use IV formulation if CrCl<50 Drug Interactions PPIs: May decrease fluconazole levels PPIs: May decrease itraconazole levels PPIs: May decrease posaconazole levels PPIs: May increase voriconazole levels May increase tacrolimus levels May increase tacrolimus levels May increase tacrolimus levels May increase tacrolimus levels Meals Capsules: food increases absorption Capsules: food increases absorption Best absorption with a high-fat meal Food may decrease voriconazole absorption Solution: food decreases absorption. Take on empty stomach Solution: food decreases absorption. Take on empty stomach Give 1 hour before or 1 hour after a meal Steady State Day 5 of therapy Day 14 of therapy Day 5 of therapy Day 5 7 of therapy in the absence of a loading dose Day 2 of therapy following a loading dose Goal Trough Concentrations (30 min prior to dose) N/A Itraconazole + hydroxyitraconazole > 1 and < 10 mcg/ml > 700 ng/ml mcg/ml Recommend Adjustments N/A < 1 mcg/ml increase dose by 50% < 700 mg/ml increase dose by 50% < 1 mcg/ml increase dose by 50% > 10 mcg/ml decrease dose by 25-50% > 5.5 mcg/ml decrease dose by 25-50% (may consider alternative agents if clinically significant toxicities) Synergy for Staphylococcus aureus: Rifampin: 10 mg/kg/dose PO q 12 hours (max single dose 600 mg) Pharmacokinetic Monitoring for Aminoglycosides and Vancomycin Peaks and troughs of aminoglycosides are monitored for efficacy and safety, beginning with the 3 rd or 4 th dose. The trough is drawn immediately before a dose; the dose is given and followed by a flush; peak is drawn 2 hours after hanging the dose. All peaks and troughs must be obtained via peripheral sticks. Desired parameters are as follows: Tobramycin: trough < 1 mg/dl; extrapolated peak mg/dl Amikacin: trough < 5 mg/dl; extrapolated peak mg/dl Usually monitor troughs only for Vancomycin. Trough is drawn immediately before the dose is due. Desired parameters are: Vancomycin: trough mg/dl BUN/SCr should be obtained twice weekly. Ensure adequate hydration and discontinue all other nephrotoxic drugs (including ibuprofen at any dose). Patients should also receive an annual hearing evaluation to evaluate for ototoxicity from aminoglycosides
11 If on vancomycin + aminoglycoside or vancomycin q6h obtain BUN/SCr three times weekly Nebulized Medications Albuterol: mg nebulized QIDPPD Hypertonic Saline: to transition patient to 7% 3% Hypertonic Saline: 5mL nebulized BID-QIDPPD 5.45% Hypertonic Saline: 4mL nebulized BID-QIDPPD 1mL 0.9% Sodium Chloride + 3mL 7% Sodium Chloride 7% Hypertonic Saline: 4mL nebulized BID-QIDPPD Dornase Alfa (Pulmozyme ): 2.5mg/2.5mL ampule nebulized QDAY - BID Use with PARI LC + nebulizer Nebulized antibiotics are administered via nebulizer after the patient s usual inhaled treatments (including bronchodilators and Dornase) and chest physiotherapy. Amikacin: Doses vary based on patient tolerance (outpatient therapy only) 250 mg nebulized BID, if tolerated increase to 500 mg nebulized BID Aztreonam: 75 mg nebulized TID Patients must supply own medication, Altera device, and cleaning supplies for inpatient use Colistin: Doses vary based on patient tolerance < 6 years: 75 mg nebulized BID > 6 years: 150 mg nebulized BID Tobramycin: 300 mg nebulized BID Vancomycin: 250 mg nebulized BID (outpatient therapy only) Other CF Therapies Pancreatic Enzyme Supplements: Use patient s home brand, OK to use home meds if not available at UNC. Infants: Initiate therapy with 1 capsule of Pancreaze 4,200 or equivalent mixed with one teaspoon of applesauce at beginning of feed. Do not place enzymes in baby bottles. Usual doses: units lipase/kg/feed. Children: Initiate therapy with units lipase/kg/meal. Usual doses are 10,000-15,000 units lipase/kg/day. Goals: Adjust doses based on degree of steatorrhea and stool frequency: 3-4 stools/day for infants; 1-2 stools/day for children and adolescents. If enzyme requirement is large (>3000 units lipase/kg/meal) consider use of a H 2 blocker (acidity inactivates enzymes). Do not exceed 3000 units/lipase/kg/meal. Doses > 20,000 units/kg/day increase risk of fibrosing colonopathy. Common Pancrelipase Products Product Dosage Form Lipase Units Amylase Units Protease Units Pancreaze 4,200 4,200 17,500 10,000
12 10,500 Capsule, enteric 10,500 43,750 25,000 16,800 coated microspheres 16,800 70,000 40,000 21,000 21,000 61,000 37,000 Creon 3,000 3,000 15,000 9,500 6,000 12,000 Capsule, enteric coated microspheres 6,000 12,000 30,000 60,000 19,000 38,000 24,000 24, ,000 76,000 Zenpep 3,000 3,000 16,000 10,000 5,000 5,000 27,000 17,000 10,000 Capsule, enteric coated microspheres 10,000 55,000 34,000 15,000 15,000 82,000 51,000 20,000 20, ,000 68,000 Vitamin D Supplementation Cholecalciferol Age Routine dosing with CF specific vitamins (IU) Step 1: Dose increases (IU) 25OH = * Step 2: Dose titration maximum (IU) 25OH = * Birth 12 months ,000 Not > 2,000 > 12 months 10 yr 800 1,000 1,600 3,000 Not > 4,000 > 10 yr 18 yr 800 2,000 1,600 6,000 Not > 10,000 > 18 yr 800 2,000 1,600 6,000 Not > 10,000 * Indicates total vitamin D (IU) intake per day, including Source CF vitamins ** Adapted from 2011 CF Update on Treatment of Vitamin D Deficiency 1 Source CF Softgel/Tablet = 1,000 units cholecalciferol ADEK/SourceCF Vitamins: 1 SourceCF chew tab = 2 ml liquid SourceCF < 1 yr: Liquid SourceCF vitamins 1 ml QDay 1-3 yr: Liquid SourceCF vitamins 2 ml QDay May initiate chewable vitamins (1 QDay) at 2 yr 3-9 yr: SourceCF chewable vitamins 1 QDay > 10 yr: SourceCF chewable vitamins 2 QDay Vitamin K: For patients receiving oral or intravenous antibiotics < 1 yr: 2.5 mg PO additional twice each week > 1 yr: 5 mg PO additional twice a week May require daily vitamin K if PT elevated at admit Salt Supplement: Add supplemental salt to newborn and infant formula and food < 6 months: 1/8 teaspoon per day
13 > 6 months 1 yr: 1/4 teaspoon per day Ursodiol: mg/kg/dose PO BID, (Max: 1000 mg/dose) Azithromycin (Anti-inflammatory) < 25 kg: 10 mg/kg/dose PO Q MWF 25 39kg: 250 mg PO Q MWF > 40 kg: 500 mg PO Q MWF REFERENCES 1. Taketomo CK, Hodding JH, Kraus DM. Pediatric Dosage Handbook, 17 th edition, Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Resp Crit Care Med 2003;168: Nelson Textbook of Pediatrics 18 th Edition by Kliegman, Behrman, Jenson, and Stanton; 2007, Elsevier, Inc Olivier KN, Yankaskas JR, Knowles MR. Nontuberculous mycobacterial pulmonary disease in cystic fibrosis. Seminars in Respiratory Infections. 1996;11(4): An official ATS/IDSA statement: Diagnosis, treatment, and prevention of nontuberculous mycobacterial disease. Am J Respir Crit Care Med. 2007;175: Zobell JT, Ampofo K, Cash J, Korgenski K, Chatfield BA. High dose ticarcillin-clavulanate administration in pediatric cystic fibrosis patients. Journal of Cystic Fibrosis 2010;9: Andes D, Pascual A, Marchetti O: Antifungal therapeutic drug monitoring: established and emerging indications. Antimicrob Agents Chemother 2009;53(1): Hope WW, Billaud EM, Lestner J, Denning DW: Therapeutic drug monitoring for triazoles. Curr Opin Infect Dis 2008;21: Pascual A et al. Voriconazole TDM in patients with invasive mycoses improves efficacy and safety outcomes. CID 2008;45: Scott LJ, Simpson D. Voriconazole: a review of its use in the management of invasive fungal infections. Drugs 2007;67: Tangpricha et al. An Update on the Screening, Diagnosis, Management and Treatment of Vitamin D Deficiency in Individuals with Cystic Fibrosis: Evidence-Based Recommendations from the Cystic Fibrosis Foundation. Ahead of Print. Revised 4/12 - Megan Young, Pharm.D.
Cystic Fibrosis: Pulmonary Exacerbations Management Guidelines
Cystic Fibrosis: Pulmonary Exacerbations Management Guidelines Inclusion Criteria: Age 1 year with cystic fibrosis admitted for a pulmonary exacerbation. Exclusion Criteria: ICU Admission Newborn with
More informationPHYSICIAN SIGNATURE DATE TIME
DRUG AND TREATMENT Condition/Status Patient Status (WCH) Patient Status: Inpatient Update Resident Team C (DEF)* A B X Vital Signs Vital Signs Q4H, Do not wake for vitals 2300-0700 (DEF)* DAILY Q4H Blood
More informationPEDIATRIC CYSTIC FIBROSIS PLAN - Phase:.
PHYSICIAN S Diagnosis Weight Allergies Patient Care Vital Signs Per Unit Standards Per Unit Standards, with Sleeping SpO2 nightly until sat greater than 92% Daily Weight Every AM In AM on Monday, Wednesday,
More informationLRI Children s Hospital
Title: Prescribing in Cystic Fibrosis Page 1 of 10 LRI Children s Hospital Prescribing in Cystic Fibrosis Staff relevant to: Clinical staff working within the UHL Children s Hospital. Team & AWP approval
More informationPEDIATRIC ACUTE ASTHMA SCORE (P.A.A.S.) GUIDELINES. >97% 94% to 96% 91%-93% <90% Moderate to severe expiratory wheeze
Inclusion: Children experiencing acute asthma exacerbation 24 months to 18 years of age with a diagnosis of asthma Patients with a previous history of asthma (Consider differential diagnosis for infants
More informationIDPH ESF-8 Plan: Pediatric and Neonatal Surge Annex Sample Pediatric Admission Orders 2015
Purpose: To provide guidance to practitioners caring for pediatric patients who need inpatient hospital care during a disaster. Disclaimer: This guideline is not meant to be all inclusive, replace an existing
More informationAsthma Care in the Emergency Department Clinical Practice Guideline
Asthma Care in the Emergency Department Clinical Practice Guideline Inclusion: 1) Children 2 years of age or older with a prior history of wheezing, and 2) Children less than 2 years of age with likely
More informationAdult Inpatient Antibiogram. Antimicrobial Susceptibilities of Frequently Recovered Clinical Isolates. January to December 2016
Adult Inpatient Antibiogram Antimicrobial Susceptibilities of Frequently Recovered Clinical Isolates January to December 2016 Department of Pathology Camille Hamula, PhD Director, Clinical Microbiology
More informationSample. Affix patient label within this box.
Instructions for completing orders Complete pages 1-3 for General Inpatient Orders. All pathway compatible orders (indicated by ) within the General Inpatient Orders will be followed automatically. Optional
More informationPhysician Orders ADULT Order Set: Respiratory Failure Orders
[R] = will be ordered Height: cm Weight: kg Allergies: [ ] No known allergies [ ]Medication allergy(s): [ ] Latex allergy [ ]Other: Admission/Transfer/Discharge [ ] Patient Status Initial Inpatient Attending
More informationAdult Dose. Adults Day 1: 1mg/kg daily Day 2: 2mg/kg daily Day 3 onwards: 3mg/kg daily. Where appropriate consider rounding dose to nearest 50mg.
AMIKACIN All ages>1month: 30mg/kg daily 1.5g once daily IV infusion over 30-60 Monitor renal function before treatment and weekly. Caution if used with other nephrotoxic drugs. Levels required. Trough
More information10/05/2017. Learning Objectives. Etiology and Prevalence. Diagnosis of Cystic Fibrosis. Disease of Childhood? Survival in Cystic Fibrosis
Management of the Cystic Fibrosis Patient Jessica Goggin, MAS, RN Nurse Manager UC San Diego Adult Cystic Fibrosis Program Learning Objectives 1. Describe the symptoms associated with Cystic Fibrosis (CF).
More informationCYSTIC FIBROSIS INPATIENT PROTOCOL PURPOSE POLICY STATEMENTS SITE APPLICABILITY PRACTICE LEVEL/COMPETENCIES DEFINITIONS EQUIPMENT
PURPOSE Physiotherapy role for inpatients with cystic fibrosis. POLICY STATEMENTS On admission to hospital all patients will be assessed by the physiotherapist within 24 hours. Physiotherapists have standing
More informationPhysician Orders PEDIATRIC: LEB Kidney Transplant Post Op Plan
Initiate Orders Phase Care Sets/Protocols/PowerPlans Initiate Powerplan Phase Phase: LEB Kidney Transplant Post Op Phase, When to Initiate: LEB Kidney Transplant Post Op Phase Admission/Transfer/Discharge
More informationPEDIATRIC LIFEGIFT BRAIN DEATH PLAN
PHYSICIAN S Diagnosis Weight Allergies Admit/Discharge/Transfer THIS PLAN IS TO BE ED ONLY ON THE LIFEGIFT ENCOUNTER, WITH DR LIFEGIFT AS THE ATTENDING. Patient Status Pt Status: Inpatient (Inpatient only
More informationMONTEFIORE MEDICAL CENTER
DEPARTMENT OF PHARMACY MONTEFIORE MEDICAL CENTER SUBJECT: MANUAL CODE: Restricted Drugs Policy, Antibiotic Restriction PH-R-5 DATE ISSUED: August, 1976 DATE REVISED: September 2000, October 2003, September
More informationEmergency Department Guideline. Asthma
Emergency Department Guideline Inclusion criteria: Patients 2 years old with: o Known history of asthma or wheezing responsive to bronchodilators presenting to the ED with cough, wheeze, shortness of breath,
More informationDiagnosis: Allergies:
Patient Name: Diagnosis: Allergies: ICU Sepsis Version 5 1/11/17 This order set must be used with an admission order set if patient not already admitted. Nursing Orders Verify that cultures have been obtained
More informationAT TRIAGE. Alberta Acute Childhood Asthma Pathway: Evidence based* recommendations For Emergency / Urgent Care
1 1 Should the child be placed into the Pathway? Asthma Clinical Score (PRAM) Inclusion Children 1 year and 18 years of age who present with wheezing and respiratory distress, and have been diagnosed by
More informationBronchiectasis. Grant Waterer. Professor of Medicine, University of Western Australia Adjunct Professor of Medicine, Northwestern University, Chicago
Bronchiectasis Grant Waterer MBBS PhD MBA FRACP FCCP Professor of Medicine, University of Western Australia Adjunct Professor of Medicine, Northwestern University, Chicago Conflicts of Interest I have
More informationSevere β-lactam allergy. Alternative (use for mild-moderate β-lactam allergy) therapy
Recommended Empirical Antibiotic Regimens for MICU Patients Notes: The antibiotic regimens shown are general guidelines and should not replace clinical judgment. Always assess for antibiotic allergies.
More informationNavigating the Hills and Valleys of CF Lung Disease: Treating Disease
This Web cast has 2 parts: Part 1 Keeping Lungs Healthy Part 2 Treating Disease Navigating the Hills and Valleys of CF Lung Disease: Treating Disease This Web cast is supported by an unrestricted educational
More informationOBSERVATION UNIT ASTHMA PATHWAY OUTLINE Westmoreland Hospital PAGE 1 OF 5
PAGE 1 OF 5 Exclusion Criteria: (Reason to admit to hospital) A. New EKG changes except sinus tachycardia B. Respiratory Rate > 40 C. Signs/symptoms of Heart Failure D. Impending respiratory failure or
More informationPHYSICIAN S ORDERS Page 1 of 5 PNEUMONIA. Resuscitation (Code)Status: Admit to: Diagnosis: Pneumonia Other: Consult:
Inpatient Observation Bed Type: Med/Surg PHYSICIAN S ORDERS Page 1 of 5 Satellite Telemetry Telemetry ICU Resuscitation (Code)Status: Admit to: Diagnosis: Pneumonia Other: Consult: Condition: Stable Guarded
More informationLIFEGIFT BRAIN DEATH PLAN
Diagnosis Weight Allergies Admit/Discharge/Transfer ***THIS PLAN IS TO BE ED ONLY ON THE LIFEGIFT ENCOUNTER, WITH DR LIFEGIFT AS THE ATTENDING*** Patient Status Pt Status: Inpatient (Inpatient only procedure)
More informationECFSPR ENCOUNTER VARIABLES (vs 1.1)
European Cystic Fibrosis Society Patient Registry ECFSPR Encounter variables vs 1 ECFSPR ENCOUNTER VARIABLES (vs 1.1) Field Name Chapter title Sub chapter title Name Clinic (for visit) Date Coding Date
More informationCystic Fibrosis Panel Applications (Dornase Alfa) Contents
Cystic Fibrosis Panel Applications (Dornase Alfa) Contents Page 2-4: Entry and Stopping Criteria for Treatment with Dornase Alfa Page 5-9: Application and consent forms for a one month trail and long term
More informationOverview of Cystic fibrosis in children. Apeksha Sathyaprasad, MD Pediatric pulmonologist
Overview of Cystic fibrosis in children Apeksha Sathyaprasad, MD Pediatric pulmonologist No conflicts of interest OBJECTIVES Review pathophysiology of pulmonary disease in cystic fibrosis Review diagnostic
More informationDrug Typical Dose CrCl (ml/min) Dose adjustment for renal insufficiency Acyclovir PO (HSV) 400 mg TID >10 <10 or HD PD
Antimicrobial Dosing in Renal Insufficiency (Adults) ASP Handbook * In patients on hemodialysis (), give antimicrobial immediately after dialysis on dialysis days. = Intermittent hemodialysis = Peritoneal
More informationEarly Pseudomonas Infection Control (EPIC) Clinical Study. Overview for Families
Early Pseudomonas Infection Control (EPIC) Clinical Study Overview for Families What is the EPIC Clinical Study? The EPIC Clinical Study Compares different treatments for children with CF who have just
More informationMortality Rate was unsightly!!! 4/24/2013. Sepsis Quality Improvement Project
Libby, MT Sepsis Quality Improvement Project Barb Dumont RN, Director of Quality and Risk Management Mike Julius RN, ED Manager Cathy Wolfe RN, Chief Nursing Officer. Mortality Rate was unsightly!!! percent
More informationInhaled Therapy - for further information, see LTHT Nebuliser Guidelines for Adults or Children
Inhaled Therapy - for further information, see LTHT Nebuliser Guidelines for Adults or Children Link to: Adult Nebuliser Guidelines Link to: Paediatric Nebuliser Guidelines and Monographs ANTIBIOTICS/
More informationPhysician Orders PEDIATRIC: LEB Critical Care Respiratory Plan
LEB Critical Care Respiratory Plan Patient Care Cardiopulmonary Monitor T;N Routine, Monitor Type: End Tidal Co2 (DEF)* T;N Routine, Monitor Type: Transcutaneous Co2 Respiratory Care Initiate Pediatric
More informationCystic Fibrosis Complications ANDRES ZIRLINGER, MD STANFORD UNIVERSITY MEDICAL CENTER MARCH 3, 2012
Cystic Fibrosis Complications ANDRES ZIRLINGER, MD STANFORD UNIVERSITY MEDICAL CENTER MARCH 3, 2012 INTRODUCTION PNEUMOTHORAX HEMOPTYSIS RESPIRATORY FAILURE Cystic Fibrosis Autosomal Recessive Genetically
More informationFacilitator s Guide. Prescription Writing/Patient Safety Author: Benjamin Estrada, MD, University of South Alabama. Active Learning Module
Facilitator s Guide Prescription Writing/Patient Safety Author: Benjamin Estrada, MD, University of South Alabama Active Learning Module Core Concepts In order to master this topic area, students must
More informationPneumonia Community-Acquired Healthcare-Associated
Pneumonia Community-Acquired Healthcare-Associated Edwin Yu Clin Infect Dis 2007;44(S2):27-72 Am J Respir Crit Care Med 2005; 171:388-416 IDSA / ATS Guidelines Microbiology Principles and Practice of Infectious
More informationAdult Institutional Pharmacokinetics Protocol
Adult Institutional Pharmacokinetics Protocol Policy Title: Clinical Pharmacokinetics (PK) Service Policy Policy Statement: It is the policy of UMHC that PK consult orders (for vancomycin or aminoglycosides)
More informationUNDERSTANDING CYSTIC FIBROSIS
UNDERSTANDING CYSTIC FIBROSIS INTRODUCTION Cystic fibrosis is a chronic disease that affects the respiratory and gastrointestinal systems. People with cystic fibrosis have a genetic defect of the lungs
More informationWheezy? Easy Peasy! The Emergent Management of Asthma & Bronchiolitis. Maneesha Agarwal MD Assistant Professor of Pediatrics & Emergency Medicine
Wheezy? Easy Peasy! The Emergent Management of Asthma & Bronchiolitis Maneesha Agarwal MD Assistant Professor of Pediatrics & Emergency Medicine Asthma Defined National Asthma Education and Prevention
More informationIR Central Venous Access [ ] Pre Procedure
IR Central Venous Access [1050200001] Pre Procedure Case Request/Scheduling Procedure Enter IR Case Request if not already completed (All hospitals except Grant Medical Center) [ ] Case Request IR Lab
More information10/6/2014. Tommy s Story: An Overview of Asthma Mangement. Disclosure. Objectives for this talk.
Tommy s Story: An Overview of Asthma Mangement Clifton C. Lee, MD, FAAP, FHM Associate Professor of Pediatrics Chief, Pediatric Hospital Medicine Children s Hospital of Richmond at VCU Disclosure Obviously,
More informationCF: Information for Case Managers. Cindy Capen MSN, RN Pediatric Pulmonary Division University of Florida
CF: Information for Case Managers Cindy Capen MSN, RN capencl@peds.ufl.edu Pediatric Pulmonary Division University of Florida About your speaker 25+ years in pulmonary Coordinator for CF Center and CF
More informationCommunity Acquired Pneumonia
April 2014 References: 1. Bradley JS, Byington CL, Shah SS, Alverson B, Carter ER, Harrison C, Kaplan SL Mace SE, McCracken Jr. GH, Moor MR, St. Peter SD, Stockwell JA, and Swanson JT. The Management of
More informationChanges in the management of children with Cystic Fibrosis. Caroline Murphy & Deirdre O Donovan CF Nurses
Changes in the management of children with Cystic Fibrosis Caroline Murphy & Deirdre O Donovan CF Nurses What Is Cystic Fibrosis? Cystic fibrosis (CF) is an inherited chronic disease that primarily affects
More informationJournal Club The ELITE Trial. Sandra Katalinic, Pharmacy Resident University Hospital of Northern British Columbia April 28, 2010
Journal Club The ELITE Trial Sandra Katalinic, Pharmacy Resident University Hospital of Northern British Columbia April 28, 2010 Overview Journal article Title, journal, authors, funding Abstract Introduction
More informationCystic Fibrosis: Progress in Treatment Management. Patrick A. Flume, M.D. Medical University of South Carolina
Cystic Fibrosis: Progress in Treatment Management Patrick A. Flume, M.D. Medical University of South Carolina Disclosures Grant support Mpex Pharmaceuticals, Inc Gilead Sciences, Inc Bayer Healthcare AG
More information2/12/2015. ASTHMA & COPD The Yin &Yang. Asthma General Information. Asthma General Information
ASTHMA & COPD The Yin &Yang Arizona State Association of Physician Assistants March 6, 2015 Sedona, Arizona Randy D. Danielsen, PhD, PA-C, DFAAPA Dean & Professor A.T. Still University Asthma General Information
More informationCYSTIC FIBROSIS OBJECTIVES NO CONFLICT OF INTEREST TO DISCLOSE
CYSTIC FIBROSIS Madhu Pendurthi MD MPH Staff Physician, Mercy Hospital Springfield, MO NO CONFLICT OF INTEREST TO DISCLOSE OBJECTIVES Epidemiology of Cystic Fibrosis (CF) Genetic basis and pathophysiology
More informationCystic Fibrosis Care Guidelines for Challenging Cystic Fibrosis
Cystic Fibrosis Care Guidelines for Challenging Cystic Fibrosis APRIL 2018 Authors Steve Kent MD, CF Clinic Director, Victoria General Hospital (VGH), Victoria Mark Chilvers MD, CF Clinic Director, B.C.
More informationCystic fibrosis: From childhood to adulthood. Eitan Kerem Department of Pediatrics and CF Center Hadassah University Hospital Jerusalem Israel
Cystic fibrosis: From childhood to adulthood Eitan Kerem Department of Pediatrics and CF Center Hadassah University Hospital Jerusalem Israel Vas deference H 2 O Cl - Na + H 2 O Na + Cl - Cl - Cl -
More informationAdmission of a Child/Young Person with Cystic Fibrosis Clinical Guideline V3.0 May 2018
Admission of a Child/Young Person with Cystic Fibrosis Clinical Guideline V3.0 May 2018 Page 1 of 16 1. Aim/Purpose of this Guideline This guideline applies to all staff caring for children/young people
More informationChildren s Hospital, LHSC Cystic Fibrosis: Paediatric Clinic
Children s Hospital, LHSC Cystic Fibrosis: Paediatric Clinic Patient Report and Review NAME: DATE OF VISIT: Please complete the following information about details of your CF Health care since your last
More informationVANCOMYCIN DOSING AND MONITORING GUIDELINES
VANCOMYCIN DOSING AND MONITORING GUIDELINES NB Provincial Health Authorities Anti-Infective Stewardship Committee Approved: May 2017 GENERAL COMMENTS Vancomycin is a glycopeptide antibiotic with bactericidal
More informationPhysician Orders ADULT: Kidney-Panc/PancTransplant Post Op Plan
Initiate Orders Phase Care Sets/Protocols/PowerPlans Initiate Powerplan Phase T;N, Phase: Kidney-Panc/Panc Transp Post Op Phase, When to Initiate: Kidney-Panc/Panc Transp Post Op Phase Vital Signs Vital
More informationAppendix D Clinical specialist statement template
Appendix D Colistimethate sodium powder and tobramycin powder for inhalation for the treatment of pseudomonas lung infection in cystic fibrosis Thank you for agreeing to give us a statement on your organisation
More information4.6 Small airways disease
4.6 Small airways disease Author: Jean-Marc Fellrath 1. INTRODUCTION Small airways are defined as any non alveolated and noncartilaginous airway that has an internal diameter of 2 mm. Several observations
More informationCommunity Acquired & Nosocomial Pneumonias
Community Acquired & Nosocomial Pneumonias IDSA/ATS 2007 & 2016 Guidelines José Luis González, MD Clinical Assistant Professor of Medicine Outline Intro - Definitions & Diagnosing CAP treatment VAP & HAP
More informationBackground. Background. Background 3/14/2014. Conflict of Interest Statement:
Platform Presentations Comparison of zolpidem to other drugs associated with falls in hospitalized patients Ed Rainville, MSPharm. Conflict of Interest Statement: The speaker has no conflict of interest
More informationDRUG ALLERGIES WT: KG
DRUG AND TREATMENT Available ONLY at: BMC-B BMC-D BMC-N BMC-S Non Categorized Quality Measure Sepsis Bundle Admit to Inpatient Patient Status: Inpatient, Level of Care: Intensive Care (8), Diagnosis: Please
More informationPHARMACOKINETICS SMALL GROUP II:
PHARMACOKINETICS SMALL GROUP II: Question 1 Why are some drug therapies initiated with a loading dose? Emphasize that LD establishes initial therapeutic level quickly. The time to reach the steady-state
More informationAMINOGLYCOSIDES DOSING AND MONITORING GUIDELINES
Approved: September 2017 AMINOGLYCOSIDES DOSING AND MONITORING GUIDELINES NB Provincial Health Authorities Anti-Infective Stewardship Committee GENERAL COMMENTS Aminoglycosides (AG) include gentamicin,
More informationPhysician Orders ADULT: LEB Asthma Admit Plan. Anticipated LOS: 2 midnights or more Patient Status Initial Outpatient T;N Attending Physician:
Initiate Orders Phase Care Sets/Protocols/PowerPlans Initiate Powerplan Phase, Phase: LEB Asthma Admit Phase, When to Initiate: LEB Asthma Admit Phase Non Categorized Add To Problem List Problem: Asthma
More informationPPP 1. Continuation, modification, and discontinuation of a medication
PRESCRIBING POLICIES: 4.7 PHARMACIST AUTHORITY The College of Pharmacists of BC Professional Practice Policy (PPP) 58 Medication Management (Adapting a Prescription) became effective April 1, 2009. The
More informationObjectives. Pneumonia. Pneumonia. Epidemiology. Prevalence 1/7/2012. Community-Acquired Pneumonia in infants and children
Objectives Community-Acquired in infants and children Review of Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America - 2011 Sabah Charania,
More informationDRUG ALLERGIES WT: KG
DRUG AND TREATMENT Available ONLY at: BMC-A BMC-B BMC-C BMC-D BMC-N BMC-S BMC-T Non Categorized SUB (SUB)* SUB Alert Protocol(SUB)* SUB Alert Protocol Lab Tests(SUB)* Quality Measure Sepsis Bundle Nursing
More informationAntibiotic Protocols for Paediatrics Steve Biko Academic Hospital
Antibiotic Protocols for Paediatrics Steve Biko Academic Hospital Respiratory tract infections in children Uncomplicated URTI A child with a cold should not receive an antibiotic Paracetamol (15 mg/kg/dose
More informationAFCH NEUROMUSCULAR DISORDERS (NMD) PROTOCOL
AFCH NEUROMUSCULAR DISORDERS (NMD) PROTOCOL A. Definition of Therapy: 1. Cough machine: 4 sets of 5 breaths with a goal of I:E pressures approximately the same of 30-40. Inhale time = 1 second, exhale
More informationNovel Therapies for NTM
NTM Lecture Series for Providers Novel Therapies for NTM Kenneth N Olivier, MD, MPH Laboratory of Chronic Airway Infection Chief, Pulmonary Branch/DIR October 20, 2017 Disclosures Past: Cooperative Research
More informationPK/PD degli antibiotici utilizzati nella sepsi
PK/PD degli antibiotici utilizzati nella sepsi Dario Cattaneo, U.O. Farmacologia Clinica ASST Fatebenefratelli Sacco, Milano Bergamo, città alta Variability of antibiotic concentrations in critically ill
More informationA Place For Airway Clearance Therapy In Today s Healthcare Environment
A Place For Airway Clearance Therapy In Today s Healthcare Environment Michigan Society for Respiratory Care 2015 Fall Conference K. James Ehlen, MD October 6, 2015 Objectives Describe patients who will
More informationOral Cystic Fibrosis Modulators
Oral Cystic Fibrosis Modulators Goals: To ensure appropriate drug use and limit to patient populations in which they have demonstrated to be effective and safe. To monitor for clinical response for appropriate
More informationCare Guideline DRAFT for review cycle 08/02/17 CARE OF THE ADULT PNEUMONIA PATIENT
Care Guideline DRAFT for review cycle 08/02/17 CARE OF THE ADULT PNEUMONIA PATIENT Target Audience: All MHS employed providers within Primary Care, Urgent Care, and In-Hospital Care. The secondary audience
More informationDornase alfa (Pulmozyme ) for cystic fibrosis. Information for patients Pharmacy
Dornase alfa (Pulmozyme ) for cystic fibrosis Information for patients Pharmacy page 2 of 8 This leaflet has been made to give you some more information to help you with your treatment. Please also read
More informationAntibiotic Dosing in the Elderly
Antibiotic Dosing in the Elderly Philip Chung, PharmD, MS, BCPS Nebraska ASAP Community Network Pharmacy Coordinator Nebraska Medicine Disclosure I have no relevant disclosure The presentation includes
More informationThe McMaster at night Pediatric Curriculum
The McMaster at night Pediatric Curriculum Community Acquired Pneumonia Based on CPS Practice Point Pneumonia in healthy Canadian children and youth and the British Thoracic Society Guidelines on CAP Objectives
More informationEmergency Department Protocol Initiative
Emergency Department Protocol Initiative ACUTE ASTHMA MANAGEMENT TOOLKIT March 2006 Provincial Emergency Services Project PHYSICIAN ORDER TEMPLATE FOR CTAS LEVEL 1 ASTHMA ADULT PEDIATRIC Date: Site: Arrival
More informationFairview Southdale Hospital Total Points: 50 RN/LPN Medication Assessment Passing: 45
Fairview Southdale Hospital Total Points: 50 RN/LPN Medication Assessment Passing: 45 1. Your diabetic patient is to be started on an insulin drip at 8 units/hour. The insulin is supplied: 100 units in
More informationPHARMACOKINETIC & PHARMACODYNAMIC OF ANTIBIOTICS
PHARMACOKINETIC & PHARMACODYNAMIC OF ANTIBIOTICS SITI HIR HURAIZAH MD TAHIR Bpharm (UKM), MSc (Clinical Microbiology) (UoN) CLINICAL PHARMACIST HOSPITAL MELAKA WHY STUDY PHARMACOKINETICS (PK) AND PHARMACODYNAMICS
More informationMAYA RAMAGOPAL M.D. DIVISION OF PULMONOLOGY & CYSTIC FIBROSIS CENTER
MAYA RAMAGOPAL M.D. DIVISION OF PULMONOLOGY & CYSTIC FIBROSIS CENTER 16 year old female with h/o moderate persistent asthma presents to the ED after 6 hours of difficulty breathing, cough, and wheezing
More informationLecture Notes. Chapter 3: Asthma
Lecture Notes Chapter 3: Asthma Objectives Define asthma and status asthmaticus List the potential causes of asthma attacks Describe the effect of asthma attacks on lung function List the clinical features
More informationPhysician Orders PEDIATRIC: LEB Oral Maxillofacial Post Op Plan
Initiate Orders Phase Care Sets/Protocols/PowerPlans Initiate Powerplan Phase Phase: LEB Oral Maxillofacial Postop Phase, When to Initiate: LEB Oral Maxillofacial Post Op Phase Admission/Transfer/Discharge
More informationWhat is Cystic Fibrosis? CYSTIC FIBROSIS. Genetics of CF
What is Cystic Fibrosis? CYSTIC FIBROSIS Lynne M. Quittell, M.D. Director, CF Center Columbia University Chronic, progressive and life limiting autosomal recessive genetic disease characterized by chronic
More informationNonparenteral medications
Nonparenteral medications Capsules and unscored tablets are rounded to the nearest whole tablet. Scored tablets are rounded to the nearest 1/2 tablet. Liquid medications are rounded to one decimal place
More informationBronchiectasis. Examples include: Viral infections (measles, adenovirus, influenza)
Bronchiectasis What is Bronchiectasis? Bronchiectasis (pronounced bron-kee-ek'-tas-is) is a condition of the airways in the lungs. These airways (bronchial tubes) are tubelike structures that branch from
More informationCARE OF THE ADULT PNEUMONIA PATIENT
Care Guideline CARE OF THE ADULT PNEUMONIA PATIENT Target Audience: The target audience for this Care Guideline is all MultiCare providers and staff, including those associated with our clinically integrated
More informationUrinary Tract Infections: From Simple to Complex. Adriane N Irwin, MS, PharmD, BCACP Clinical Assistant Professor Ambulatory Care October 25, 2014
Urinary Tract Infections: From Simple to Complex Adriane N Irwin, MS, PharmD, BCACP Clinical Assistant Professor Ambulatory Care October 25, 2014 Learning Objectives Develop empiric antimicrobial treatment
More informationBronchiectasis. What is bronchiectasis? What causes bronchiectasis?
This factsheet explains what bronchiectasis is, what causes it, and how it is diagnosed and managed. More detailed information is available on the Bronchiectasis Patient Priorities website: www.europeanlunginfo.org/bronchiectasis
More informationUpper...and Lower Respiratory Tract Infections
Upper...and Lower Respiratory Tract Infections Robin Jump, MD, PhD Cleveland Geriatric Research Education and Clinical Center (GRECC) Louis Stokes Cleveland VA Medical Center Case Western Reserve University
More informationa. Will not suppress respiratory drive in acute asthma
Status Asthmaticus & COPD with Respiratory Failure - Key Points M.J. Betzner MD FRCPc - NYEMU Toronto 2018 Overview This talk is about the sickest of the sick patients presenting with severe or near death
More informationNeutropenic Fever. CID 2011; 52 (4):e56-e93
Neutropenic Fever www.idsociety.org CID 2011; 52 (4):e56-e93 Definitions Fever: Single oral temperature of 101 F (38.3 C) Temperature 100.4 F (38.0 C) over 1 hour Neutropenia: ANC < 500 cells/mm 3 Expected
More informationPA Update: Oral Cystic Fibrosis Modulators
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationCarole Wegner RN, MSN And Lori Leiser CRT
Airway Clearance Carole Wegner RN, MSN And Lori Leiser CRT Topics Suctioning and suctioning equipment Medications to facilitate t airway clearance Bronchial hygiene modalities Preparing for suctioning
More informationST. DOMINIC-JACKSON MEMORIAL HOSPITAL JACKSON, MISSISSIPPI
Date & Time TAVR Pre-Op Admission Clinical Pathway Page 1 of 3 1. Admit as INPATIENT to Dr.. For Surgery Today or Tomorrow 3. Diagnosis: 4. Allergies: Pharmacy Mnemonic: PRETAVR 5. Vital signs on arrival.
More informationDilemmas in Septic Shock
Dilemmas in Septic Shock William Janssen, M.D. Assistant Professor of Medicine National Jewish Health University of Colorado Denver Health Sciences Center A 62 year-old female presents to the ED with fever,
More information3002 Seminar. Problem-Based Learning: Evaluating and Managing the Patient with Recurrent Infections DO NOTE TURN THE PAGES UNTIL INSTRUCTED TO DO SO!
3002 Seminar Problem-Based Learning: Evaluating and Managing the Patient with Recurrent Infections DO NOTE TURN THE PAGES UNTIL INSTRUCTED TO DO SO! Discussion leaders: Kenneth Paris, MD Richard L. Wasserman,
More informationInteresting cases in fungal asthma
Interesting cases in fungal asthma Ritesh Agarwal MD, DM Professor of Pulmonary Medicine Postgraduate Institute of Medical Education and Research Chandigarh, India Fungal asthma Broadly defined as the
More informationPediatric Respiratory Infections
Pediatric Respiratory Infections Brenda Kelly PharmD BCPS Residency Program Director Virginia Mason Memorial, Yakima, Washington brendakelly@yvmh.org Disclosure The presenter has no actual or potential
More informationAntimicrobial Management of Febrile Neutropenic Sepsis
Antimicrobial Management of Febrile Neutropenic Sepsis Written by: Dr J Joseph, Consultant Haematologist Dr K Gajee, Consultant Microbiologist Amended by: Larissa Claybourn, Antimicrobial Pharmacist Date:
More informationNontuberculous Mycobacteria (NTM) in Patients with Cystic Fibrosis
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/cystic-fibrosis-in-focus/nontuberculous-mycobacteria-ntm-in-patientswith-cystic-fibrosis/8337/
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE 1 Guideline title SCOPE Bronchiolitis: diagnosis and management of bronchiolitis in children. 1.1 Short title Bronchiolitis in children 2 The remit The
More information